Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)’s Quarterly Revenue

Prestige Consumer Healthcare Inc. (NYSE:PBH) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Prestige Consumer Healthcare Inc. (NYSE:PBH) stands fifteenth on our list of best healthcare stocks.

TheFly reported on February 6 that Canaccord reduced its price target on PBH to $86 from $88 and maintained a Buy rating on the shares. The change came after the company reported fiscal third-quarter sales of $283.4 million, a 2.4% year-over-year decline. This amount was roughly in line with company projections and came in just over the $282.0 million that the Street had anticipated. According to management, the Clear Eyes brand’s supply issues were the main cause of the sales drop.

Moreover, on February 5, Prestige Consumer Healthcare Inc. (NYSE:PBH) reported third-quarter net income, which totaled $46.7 million, while adjusted net income reached $54.9 million. Diluted EPS of $0.97, while adjusted diluted EPS came in at $1.14, compared with $1.22 in the same quarter last year. The company also finalized the acquisition of Pillar5 Pharma and repurchased about 0.8 million shares during the quarter. While maintaining projections for free cash flow of at least $245 million, the corporation also reduced its fiscal 2026 sales outlook to about $1.1 billion.

Prestige Consumer Healthcare Inc. (NYSE:PBH) is a U.S. over-the-counter healthcare company that markets and innovates trusted wellness brands and continuously improves products to meet evolving consumer needs while expanding its portfolio and global reach in OTC care.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.